Eleven Biotherapeutics ^{Priced, Nasdaq: EBIO}

Clinical-stage biotech developing protein therapeutics to treat dry eye diseases.

Industry: Health Care

First Day Return: +8.5%

EBIO

Clinical-stage biotech developing protein therapeutics to treat dry eye diseases.

IPO News for Eleven Biotherapeutics

US IPO Recap: Revance jumps 68% in ten-IPO week 02/10/14
Eleven Biotherapeutics prices IPO at $10, below the range 02/06/14
12 US IPOs planned for the week of Feb 3 02/03/14

IPO Data
IPO Date	02/05/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$50
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Headquarters	Cambridge, MA, United States
Founded	2008
Employees at IPO	16
Website www.elevenbio.com

IPO News for Eleven Biotherapeutics

US IPO Recap: Revance jumps 68% in ten-IPO week 02/10/14
Eleven Biotherapeutics prices IPO at $10, below the range 02/06/14
12 US IPOs planned for the week of Feb 3 02/03/14

Eleven Biotherapeutics (EBIO) Performance